Orphazyme A/S (ORPHA.CO)

DKK 1120.0

(-2.61%)

Net Income Summary of Orphazyme A/S

Orphazyme A/S's latest annual net income in 2023 was -26.04 Million DKK , up 76.45% from previous year.
Orphazyme A/S's latest quarterly net income in 2024 Q2 was 924 Thousand DKK , down 0.0% from previous quarter.
Orphazyme A/S reported an annual net income of -110.59 Million DKK in 2022, up 82.35% from previous year.
Orphazyme A/S reported an annual net income of -626.53 Million DKK in 2021, up 1.06% from previous year.
Orphazyme A/S reported a quarterly net income of 924 Thousand DKK for 2024 Q2, down 0.0% from previous quarter.
Orphazyme A/S reported a quarterly net income of -13.26 Million DKK for 2023 Q4, down -100.0% from previous quarter.

Annual Net Income Chart of Orphazyme A/S (2023 - 2015)

Historical Annual Net Income of Orphazyme A/S (2023 - 2015)

Year	Net Income	Net Income Growth
2023	-26.04 Million DKK	76.45%
2022	-110.59 Million DKK	82.35%
2021	-626.53 Million DKK	1.06%
2020	-633.24 Million DKK	-87.63%
2019	-337.49 Million DKK	-46.99%
2018	-229.6 Million DKK	-81.93%
2017	-126.2 Million DKK	-117.84%
2016	-57.93 Million DKK	-21.42%
2015	-47.71 Million DKK	0.0%

Year	Net Income	Net Income Growth
2024 Q1	924 Thousand DKK	106.97%
2024 Q2	924 Thousand DKK	0.0%
2023 Q4	-13.26 Million DKK	-100.0%
2023 Q3	-6.63 Million DKK	48.12%
2023 Q1	-6.39 Million DKK	82.54%
2023 Q2	-12.78 Million DKK	-100.0%
2023 FY	-26.04 Million DKK	76.45%
2022 Q1	-12.22 Million DKK	92.49%
2022 Q4	-36.61 Million DKK	0.0%
2022 FY	-110.59 Million DKK	82.35%
2022 Q2	-82.83 Million DKK	-577.71%
2021 Q1	-27.5 Million DKK	92.8%
2021 FY	-626.53 Million DKK	1.06%
2021 Q3	-81.37 Million DKK	82.45%
2021 Q4	-162.75 Million DKK	-100.0%
2021 Q2	-463.78 Million DKK	-1586.41%
2020 Q1	-125.7 Million DKK	27.58%
2020 FY	-633.24 Million DKK	-87.63%
2020 Q4	-381.83 Million DKK	-100.0%
2020 Q3	-190.91 Million DKK	24.06%
2020 Q2	-251.41 Million DKK	-100.0%
2019 Q1	-81.95 Million DKK	-34.58%
2019 Q3	-86.79 Million DKK	47.05%
2019 Q2	-163.9 Million DKK	-100.0%
2019 Q4	-173.58 Million DKK	-100.0%
2019 FY	-337.49 Million DKK	-46.99%
2018 Q3	-60.89 Million DKK	-12.98%
2018 Q4	-60.89 Million DKK	0.0%
2018 Q2	-53.9 Million DKK	0.0%
2018 FY	-229.6 Million DKK	-81.93%
2018 Q1	-53.9 Million DKK	-45.52%
2017 Q2	-26.06 Million DKK	0.0%
2017 Q3	-37.04 Million DKK	-42.13%
2017 Q4	-37.04 Million DKK	0.0%
2017 FY	-126.2 Million DKK	-117.84%
2017 Q1	-26.06 Million DKK	-72.88%
2016 Q4	-15.07 Million DKK	0.0%
2016 FY	-57.93 Million DKK	-21.42%
2016 Q2	-13.89 Million DKK	0.0%
2016 Q1	-13.89 Million DKK	0.0%
2016 Q3	-15.07 Million DKK	-8.5%
2015 FY	-47.71 Million DKK	0.0%

Peer Net Income Comparison of Orphazyme A/S

Name	Net Income	Net Income Difference
ALK-Abelló A/S	486 Million DKK	105.36%
Bavarian Nordic A/S	1.47 Billion DKK	101.766%
Genmab A/S	4.35 Billion DKK	100.599%
Gubra A/S	-44.52 Million DKK	41.497%
Novo Nordisk A/S	83.68 Billion DKK	100.031%
Pharma Equity Group A/S	-24.6 Million DKK	-5.847%
Zealand Pharma A/S	-703.73 Million DKK	96.299%